CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 17 enrolled
Drug / intervention
Regorafenibdrug
Likely dose
Regorafenib 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02459119
NCT02459119Phase 2Completed
CompareCT.gov

A Multicenter, Non-Randomized, Phase II Study of Regorafenib for Advanced Urothelial Cancer Following Prior Chemotherapy

University of Alabama at Birmingham·interventional·Posted Jun 1, 2015·Updated Aug 6, 2020

In Brief

A Phase 2 clinical trial evaluating Regorafenib for Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer). Completed, enrolled 17 participants across 3 sites.

Detailed Summary

This study will test how well Regorafenib controls disease progression in urothelial cancer (cancer occurring in the urinary bladder, ureters, or renal pelvis) following previous therapy with chemotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
CountriesUnited States
CollaboratorsBayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 1, 2015
Enrollment StartMay 1, 2015
Primary CompletionFeb 1, 2019
Study CompletionApr 1, 2020
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 11.1 years ago

Interventions

Regorafenibdrug

Regorafenib will be packaged as 40 mg tablets in a bottle. Patients will be instructed to maintain a daily medication calendar.